Biocon Pharma Inc. announced the FDA approval of its generic version of Mycophenolate Sodium for Oral Suspension, marking a strategic expansion in its immunosuppressive portfolio. This approval allows the company to directly challenge specialized competitors in the transplant market, expected to drive new revenue streams and enhance profitability.